Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002812 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
A Phase 3 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,078
- Enrollment target
- 20
- Study locations
NCT00002812: Completed Phase 3 study of Leukemia, sponsored by Children's Oncology Group.
NCT00002812 is a Phase 3 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 2,078 participants, above the 478-participant average among 233 other Leukemia trials with a reported enrollment target (335% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002812, a Phase 3 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,078 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Primary Outcome
The primary outcome index used in examining most of the randomized treatment groups will be event-free survival (EFS).
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Long Beach Memorial Medical Center - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Cancer Center and Cancer Research Institute - San Francisco
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
- Mount Sinai School of Medicine - New York
- Herbert Irving Comprehensive Cancer Center - New York
Minnesota
- University of Minnesota Cancer Center - Minneapolis
- Mayo Clinic Cancer Center - Rochester
Colorado
- Children's Hospital of Denver - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
Iowa
- Holden Comprehensive Cancer Center at The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,078 participants |
| Start Date | 1996-09 |
| Phase | Phase 3 |
What the finished NCT00002812 record still lists
NCT00002812 is an interventional study that assigns participants to a tested intervention. Its 2,078 participants enrollment target places it among the larger protocols in the corpus, above the 478-participant average among 233 other Leukemia trials with a reported enrollment target (335% higher).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002812 names 20 study sites across 12 states, led by California, New York, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00002812 about?
NCT00002812 is a clinical study titled "Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standa...
What is the current status of trial NCT00002812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,078 participants. The study started on 1996-09.
What conditions does trial NCT00002812 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00002812?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002812?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002812 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002812's enrollment target sits among peer trials
2,078 6th of 233 higher than 228 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373564 · 2,076 participants · Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia